Back to News
Market Impact: 0.45
BioNTech's BNT113 Misses Progression-Free Survival Endpoint In Phase 3 Head And Neck Cancer Trial
Source: Nasdaq
Healthcare & BiotechCompany Fundamentals
BioNTech said its AHEAD-MERIT Phase 2/3 trial of BNT113 plus pembrolizumab did not meet the primary endpoint of progression-free survival versus pembrolizumab alone. The result is negative for the trial’s evaluation in patients with HPV16-positive head and neck cancer; the article provides no additional trial results or market reaction.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately negative
Sentiment Score
-0.55
Ticker Sentiment
BNTX-0.80
More News
- South Korean carmaker Hyundai plans 'strategic' investment of $15.5 billion in India by 2032
- Applied Materials’ $5 billion AI lab aims to cut chip development time in half—and restore Silicon Valley’s edge
- Wells Fargo CFO on Earnings, Deals, Consumer Strength
- Bank of America hit with more than $1.2 billion in penalties over money-laundering violations
- Meta’s Muse models reach the AI frontier—and kill any hopes to ‘pace’ it
- We're upgrading our Goldman Sachs rating after a strong quarter bodes well for the future
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- Palantir (PLTR) Q4 2025 Earnings: 70% Revenue Growth, Then an 11% Single-Day Crash
- AlphaSense Pricing: What Public Contract Data Shows in 2026